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The Organization of European Cancer Institutes (OECI) is a non-
governmental, non-profit organization founded in Vienna in 1979.
Initially, its main objectives were to improve communication
between European cancer institutions and to increase collaboration
between them. Evolving healthcare programs over the past 10
years have given the OECI the opportunity to take up new chal-
lenges. The expertise of members within the organization has
enabled the OECI to address the problem of quality in cancer care
on a European scale and to develop initiatives to improve the
overall management and outcome of cancer patients. The
assembly of the OECI has subsequently been able to set up
specific working groups on the following topics: clinical practice
guidelines, data monitoring and evaluation, economic evaluation,
pre-clinical and clinical research, medical education, communica-
tion with cancer patients and the use of information technology
and telemedecine. Within the context of cancer care, many of these
approaches have already been shown to be important in routine
daily practice, not only within specialized cancer centres, but also
across all centres and institutions involved in cancer care. The
OECI provides an excellent forum to pursue research in these
areas and bids for research funds from the European Community
(Organization of European Cancer Institutes, 2000). 
In 1996, Andre Kuwalowski, the former president of the OECI
asked the members for topics they particularly wanted to address.
The development and dissemination of clinical practice guidelines
was identified as a topic of high priority and one that is essential
for improving the quality of care of cancer patients. It is recog-
nized that guidelines must be implemented within a larger project
that includes quality control, to show that where they are
empolyed, patient outcome is better (Langmark, 1997). 
In order to avoid duplication of effort, the programme
committee decided to adopt, disseminate and implement guide-
lines that had already been produced. It was initially planned to
use the National Cancer Institute’s comprehensive cancer data-
base PDQ® as a starting point. However, it soon became clear
that various European institutions had already developed their
own guidelines at a local, regional or national level. The
Standards, Options & Recommendations (SOR) project was
developed by the French National Federation of Cancer Centers
(FNCLCC) and the 20 French Comprehensive Cancer Centres
(CRCC) in collaboration with specialists from French public
universities, general hospitals, private clinics and scientific soci-
eties. The program deals specifically with guidelines in cancer
care (Fédération Nationale des Centres de Lutte Contre le Cancer,
1998) that are developed according to explicit quality criteria.
Critical appraisal of the available evidence by multidisciplinary
expert groups is an approach highly relevant to clinical practice in
oncology. 
The SOR documents are published widely in print in the form of
monographs and articles and in electronic form. A CD-ROM is avail-
able (Fédération Nationale des Centres de Lutte Contre le Cancer,
1998) covering 25 different cancers, with others under development. 
As with other guideline development programs, the SOR project
uses ‘levels of evidence’ to inform the user of the evidence on which
the recommendations are based. The classification used by the SOR
program distinguishes five levels of evidence and takes into account
not only the type of study but also the accordance or disagreement
between trials (Bailar, 1997 LeLorier et al, 1997). This emphasizes
the need for explicit criteria to be able to critically appraise the
evidence and for the transparent reporting of guidelines (Lee et al,
2000; Therasse et al, 2000). It also highlights the need for high quality
research in the development of high quality guidelines and ensures
there are no conflicting situations (Marshall, 2000). It is also clear that
even in cancer research, guidelines are essential (United Kingdom
Co-ordinating Committee on Cancer Research, 2000). 
To date, the language of the French version has been a limiting
factor. Sections of the SORs have been translated into English,
however, and can thus be distributed throughout Europe. A trans-
parent guideline development and reporting process is necessary
for the use of SOR guidelines by the OECI and its member insti-
tutions. This is essential in order to assess to what extent the
guidelines can be used across borders, and at which points in the
development process specific local input is needed so that the
guidelines are relevant for the setting in which they are to be
used. A potential problem with respect to the use of these guide-
lines throughout Europe is that, where the evidence is weak,
there can be sociocultural differences between countries. The
next step must be to translate the guidelines into other European
languages. 
Cancer care based on clinical practice guidelines can contribute
to an improvement in outcome for cancer patients (Organization of
European Cancer Institutes, 2000) and may contribute to the
reduction in the significant differences in outcome between
different European countries (Quinn et al, 1998). Perhaps the most
important feature of the SORs for future practice is that they
provide clinical algorithms as an aid for clinicians managing
different clinical situations in daily practice. Looking to the future
however, the impact of guidelines on outcome can only be shown
if all cancer cases are accurately registered (Dickman et al., 1999). 
The OECI has decided to collaborate with the FNCLCC and
CRCCs in the translation and publication of the SORs, to make
them available to all OECI member institutions. The OECI will
also contribute to help maintain a regular updating program. The
OECI will distribute SOR guidelines to all members and collabo-
rating institutions, which have as their ultimate target the improve-
ment of cancer care. 
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